Provention Bio

$6.95 0.00% ($0.00)
  • 1D
  • 1W
  • 1M
  • 1Y
  • 5Y
  • YTD

Get ready to invest

Subscribe

About Provention Bio

Provention Bio, Inc. is a clinical-stage biopharmaceutical company that develops therapeutics targeting immune-mediated diseases. The Company aims at developing therapies for disease that include type one diabetes (T1D), Crohn’s disease, ulcerative colitis, lupus and other viral diseases. The Company’s principal product candidates include PRV-031, PRV-6527, PRV-300, PRV-3279, and PRV-0101.PRV-031 is a product candidate in its Phase III clinical trial that is developed for the interception of T1D. PRV-6527 is an oral CSF-1R inhibitor for the treatment of Crohn’s disease. PRV-300 is developed for the treatment of ulcerative colitis. PRV-3279 is developed to treat lupus disease. PRV-101 is a multivalent coxsackie virus (CVB) vaccine for the prevention of acute CVB and the prevention of the onset of T1D.

Stock Analysis

last close $6.9
1-mo return 10.2%
3-mo return 2.8%
avg daily vol. 980.29T
52-week high 20.05
52-week low 5.59
market cap. $445M
forward pe -
annual div. -
roe -89.9%
ltg forecast -
dividend yield -
annual rev. $1M
inst own. 35.8%
baraka

Subscribe now for daily local and international financial news

Subscribe